Osteoporosis Screening in High-Risk Men A VA Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician https://t.co/Kt3mJLahdq

Retrospective study of 42 adult Still' pts Rx after 2010 w/ IL‐1 inhib if given < 6 mos (early) or > 6mos of Sxs. Early IL-1i had more inactive dz (CID)(67% vs 38%; P = 0.17) & steroid d/c w/in 6 mos. 10 major flares observed (62% after IL‐1i suspension or spacing) https://t.co/uD1meQuYvj

Not all difficult-to-treat RA will have rapid radiographic progression A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy. https://t.co/WrwyeW5qsj

Optimizing DMARD Therapy in Rheumatoid Arthritis A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare. https://t.co/37O3mAulGy https://t.co/y7OkkzRZUg

RheumNow is LIVE from #ACR25 Oct 24–29. KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed. https://t.co/pPwJNOyEFU

Associations in Rheumatology (10.3.2025) Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow. https://t.co/pnLoquR4By https://t.co/PKJuxMGrZy

Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92

Ethnic Minority Rheumatoid Arthritis Consortium registry study of 1315 RA pts (Dz duration 10yrs) incl 29% Blacks found Blacks in less remission(~2-fold by DAS28), more mod-hi dz activity, & frequently met active disease eligibility for RCTs. https://t.co/SfkVUB1GBz https://t.co/OwvmALHPFA

German survey of 124 AOSD pts - Dz duration 7 yrs (Dx delay 2 yrs), 2/3 on biologics, 84% responding, 81% inactive by CRP. MDs report 35% of pts Sx-free. More Patients report Persistent Sxs LBP (39.5%), fatigue/weakness (39%), & joint inflammation (27%). https://t.co/2FGUPrhB8H

Phase 3 RCT Cannabis sativa DKJ127 (VER-1) in 820 chronic low back pain (cLBP) pts. Primary endpt at wk 12 showed pain reduction of −1.9 NRS VER-01 vs −0.6 PBO (P < 0.001). Pain further decreased to −2.9 w/ 6 mos OL Rx. VER-1 was well tolerated. No addiction https://t.co/IeCV8tU2WR

Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/nbdZfBDukE